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Purpose: To describe a case of tamoxifen toxicity superimposed on central serous chorioretinopathy
(CSCR). We review the role of estrogen and the effect of tamoxifen on ocular tissues.
Observations: A 32-year-old Hispanic female with inﬁltrating ductal carcinoma of the left breast
(T2N1M0, triple-positive), status post chemotherapy and bilateral mastectomy, presented with
complaint of a ﬂoater and decreased central vision of the right eye (OD). Symptoms began three weeks
after initiating tamoxifen and ﬁve months after the last cycle of chemotherapy and dexamethasone.
Visual acuity (VA) was 20/30 OD at presentation. Clinical examination and multimodal imaging revealed
subretinal ﬂuid (SRF) and pigment epithelial detachment (PED) suggestive of CSCR. After one month of
monitoring, VA improved to 20/20; there was SRF resolution, small PED, and focal ellipsoid zone (EZ)
band loss. Two weeks later, after undergoing surgery and starting a topical steroid, she returned with
count ﬁngers (CF) VA and large SRF OD. Steroid cessation improved SRF after one month, but VA was
unchanged. Tamoxifen was discontinued, and VA improved to 20/100 with near-complete resolution of
SRF at three weeks, and signiﬁcant reduction in choroidal thickness at two months. At ﬁnal follow-up, VA
was 20/200, and there was focal EZ band loss sub-foveally, minimal SRF, and small PED.
Conclusions and Importance: Treatment with tamoxifen may lead to ocular toxicity and can complicate
the recovery course of patients affected with CSCR. Variations in levels of the estrogen receptor-alpha
(ER-a) and treatment with tamoxifen (ER-a partial agonist) may lead to loss of the protective effect of
estrogen in the retinal pigment epithelial cells in premenopausal women. Furthermore, tamoxifen
toxicity can lead to focal photoreceptor loss. Treatment in these cases should be coordinated together
with the oncologist.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tamoxifen is an important, potentially life-savingmedicine used
in the treatment of patients with hormone-receptor positive breast
cancer.[1] It is a selective estrogen receptormodulator that is usually
well tolerated. Common systemic side effects include nausea,
vomiting, rash, hot ﬂashes, and mood changes, but more severe
systemic and ocular side effects are rare. When ocular toxicity re-
sults, vision loss can be greatly disturbing to the patient, and may50 San Pablo Street, 4th ﬂoor,
ani).
Inc. This is an open access article uresult from crystalline retinopathy, macular edema, or optic
neuritis amongst other toxicities.[2] Advances in ophthalmic im-
aging modalities have allowed for greater characterization and
understanding of this toxicity. Herewe describe a case of tamoxifen
toxicity with a novel presentation, which posed a clinical dilemma.
2. Case Report
A 32-year-old Hispanic, premenopausal female with history of
inﬁltrating ductal carcinoma of the left breast (T2N1M0, ER/PR/
HER2 positive), status post chemotherapy, bilateral mastectomy,
and reconstruction surgery, presented with complaint of a ﬂoater
and decreased central vision of the right eye (OD), which started
the prior evening. She characterized the deﬁcit as a small, dark areander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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diplopia, ocular pain, and other ocular symptoms. She noted no
changes in her left eye. She reported no previous ocular problems
or trauma. She denied fever, chills, headaches, nausea, vomiting,
rashes, tinnitus, and joint pain. She provided written consent to
include her medical information in this report.
Five months prior, the patient had completed six cycles over
ﬁfteen weeks of neoadjuvant chemotherapy with docetaxel
(125 mg), carboplatin (900 mg), trastuzumab (540 mg), and per-
tuzumab (840 mg) administered intravenously at each cycle.
Included in this peri-chemotherapy regimen was daily dexameth-
asone (8 mg oral), monthly leuprolide (7.5 mg intramuscular), and
pegﬁlgrastim (6 mg subcutaneous) injected once per chemo-
therapy cycle. She suffered one episode of neutropenic fever, but
otherwise her course was well tolerated. Next, she underwent left
modiﬁed radical mastectomy and right prophylactic mastectomy
with immediate reconstruction bilaterally, and she declined radi-
ation therapy. Her surgical history and past medical history were
otherwise unremarkable; she denied obstructive sleep apnea and
family history of ocular disease or cancer. She denied tobacco or
drug use, and drank limited alcohol socially. She also denied the use
of steroids, inhalers, and energy drinks within the past ﬁve months.
At the time of ophthalmic evaluation, ﬁve months had passed
since her last cycle of chemotherapy and dexamethasone, and her
only active medications were low-dose, oral tamoxifen (20 mg
daily; initiated three weeks prior) and intravenous trastuzumab
(540 mg every three weeks; initiated eight months prior). Best-
corrected visual acuity (BCVA) was 20/30 OD and 20/25 in the
left eye (OS). Intraocular pressure was 19 in both eyes (OU). Pupils
were round and reactive with no afferent pupillary defect. Extra-
ocular movements were full OU. Confrontation visual ﬁelds were
full. Amsler grid was normal, and Ishihara color plates were 8 of 8 in
each eye. Slit lamp and dilated fundus exam were normal, except
for vitreous syneresis OU andmacular edema OD (Fig.1A&D; Optos,
Marlborough, MA).
Spectral domain optical coherence tomography (SD-OCT; Cirrus
5000, Carl Zeiss Meditec, Inc., Dublin, CA) revealed a large amount
of subretinal ﬂuid (SRF) and detachment of the neurosensory
retina, resulting in disruption of the foveal contour and two un-
derlying retinal pigment epithelial detachments (PED) OD. AlsoFig. 1. A. Wide-ﬁeld color photograph revealing normal appearance of the optic nerve, ves
spectral domain optical coherence tomography (SD-OCT) of the macula OD revealing an en
with disruption of the foveal contour and a retinal pigment epithelial detachment. Ther
photograph revealing normal appearance of the optic nerve, macula, vessels, and peripherynoted were few, small, hyperreﬂective foci in the outer plexiform
layer (OPL; Fig. 1BeC). SD-OCT macula OS was normal (Fig. 1EeF).
Fluorescein angiography revealed small foci of hyperﬂuorescence
inferior to the fovea, which began early during the arterial phase
and increased slightly in intensity and size on later phases, local-
izing to the PED, consistent with an expansile dot pattern (Fig. 2;
Optos). She was counseled that she had clinical ﬁndings suggestive
of central serous chorioretinopathy. We recommended steroid
avoidance, stress reduction if possible, and decided to monitor
closely.
She returned one month later with subjective improvement in
vision, as well as improvement in BCVA to 20/20 OU. We noted
marked reduction of SRF with a small PED remaining, and focal,
granular hyperreﬂectivity and loss of the EZ band subfoveally,
above the PED OD (Fig. 3A; Spectralis, Heidelberg, Germany). We
opted to continue to monitor. As she continued to do well, she
cancelled her follow-up appointment. During that time, she un-
derwent revision of her reconstructive breast surgery and concur-
rently developed a rash above her eyebrows, which she self-treated
with an over-the-counter, topical hydrocortisone 1% cream.
She presented two weeks later with sudden and severe wors-
ening of her vision to count ﬁngers OD and with extensive SRF OD,
more severe than on initial presentation (Figs. 3B and 4A; Spec-
tralis). Autoﬂuorescence OS was normal (Fig. 4B). Her choroidal
thickness OD and OS measured an average of 443 ± 44.3 mm
(491 mm subfoveally) and 405 ± 43.1 mm (432 mm subfoveally),
respectively (Fig. 5AeB). We counseled her to stop the hydrocor-
tisone cream, discussed various treatment options, and after dis-
cussion of the risks and beneﬁts, we decided to monitor closely and
follow-up in one month. At this next visit, after cessation of topical
steroid, her vision had not improved despite a reduction in SRF.
Given these ﬁndings, after discussionwith her oncologist, we asked
her to discontinue the tamoxifen, ﬁve months after its initiation.
Three weeks later, vision improved to 20/200 OD with near-
complete resolution of SRF but with persistent PED and focal loss
of the EZ band subfoveally on OCT (Fig. 3C). One month later, we
noted a statistically signiﬁcant reduction in choroidal thickness OD
(p < 0.01; compare Fig. 5A and C), with no difference in OS
(p ¼ 0.35; compare Fig. 5B and D; DRI OCT-1, Topcon Medical
Systems, Oakland, NJ). Four months after cessation of tamoxifen,sels, and periphery, but signiﬁcant edema in the macula OD. B-C. Fundus overlay and
larged foveal avascular zone corresponding to a large amount of subretinal ﬂuid (SRF)
e are foci of hyperreﬂectivity within the outer plexiform layer. D. Wide-ﬁeld color
OS. EeF. Fundus overlay and SD-OCT of the macula OS, which is normal in appearance.
Fig. 2. AeD. Fluorescein angiography OD, revealing small foci of hyperﬂuorescence, which is subtle in appearance early during the arterial phase and increases mildly in size and
intensity through the late phases, consistent with an expansile dot pattern.
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microperimetry (MP-1, Nidek Technologies, Italy; Fig. 6AeB), and
clinical exam and OCT ﬁndings remained stable. At sixteen-month
follow-up, BCVA remained stable at 20/200.3. Discussion
The ATLAS trial demonstrated that ten years of tamoxifen
therapy is more beneﬁcial than the current ﬁve-year standard of
therapy for hormone-receptor positive breast cancer.[1] Meanwhile,
the incidence of tamoxifen ocular toxicity is estimated to be be-
tween 0.9% and 12%.[3] It is likely that certain patients will be
treated with tamoxifen for longer periods.[1] It is not known
whether this will be accompanied by an increase in the number of
cases of drug-related ocular toxicity.
Ocular manifestations of tamoxifen toxicity include but are not
limited to crystalline retinopathy, optic neuropathy, macular
edema, pseudocystic foveal cavitation, and corneal deposits.[2,4]
When ocular toxicity occurs, the treatment is to stop tamoxifen.
There have not been reports of an efﬁcacious antidote, though
corticosteroid use for tamoxifen-induced optic neuropathy has
been attempted with only transient improvement in visual acu-
ity.[5] OCT ﬁndings have included crystalline deposits in the inner
retina, EZ band loss, thinning of the inner retina and cystic foveal
cavitation, corresponding to hyperﬂuorescence on FA, without
leakage.[4] Toxicity to the retina has been irreversible even after
cessation.[2] While ocular toxicity has occurred with high dose
therapy (180 mg daily; cumulative dose >100 g) [6], it has also
occurred at low dose (20 mg daily), after as little as 0.42 g cumu-
lative dose, within three weeks of initiating therapy.[5]
Our patient presented with ocular ﬁndings three weeks after
initiating tamoxifen (cumulative dose 0.42 g). Her clinical exam,OCT, and FA ﬁndings including SRF with PED and expansile dot
pattern were consistent with the typical angiographic and clinical
signs of CSCR; however, the extent of her vision loss and poor ﬁnal
visual acuity may have been related to her tamoxifen treatment
rendering her retinal pigment epithelium (RPE)more susceptible to
damage from a CSCR episode. She did not have the typical risk
factors for CSCR, except for stress at work and bilaterally enlarged,
choroidal thickness, and she denied recent steroid use, energy
drinks, or history of OSA. Furthermore, she had completed a ﬁfteen-
week course of oral steroids ﬁve months prior to presentation
without symptoms. Nevertheless, within three weeks of initiating
tamoxifen, the patient presented to clinic, and three weeks after
tamoxifen cessation (cumulative dose 3.08 g), the patient had her
greatest improvement. Her vision improved from CF to 20/100, SRF
improved substantially, and choroidal thickness OD improved
signiﬁcantly. While tamoxifen cessation coincided with improve-
ment, the natural history of CSCR alone could have been respon-
sible for the ﬂuid resolution. Nevertheless, the patient’s worse than
expected visual outcome and severe disruption of the EZ band
subfoveally may have been due to superimposed, tamoxifen-
induced RPE damage. Perhaps, she suffered “two hits” e one from
CSCR and one from tamoxifen, damaging the RPE and leading to her
devastating sequelae.
Tamoxifen is a partial agonist, which activates the estrogen
receptor-alpha (ER-a) with lower efﬁcacy compared to estrogen, its
natural ligand. When tamoxifen binds ER-a, it produces a net
decrease in ER-a activation compared to the response observed
when estrogen is bound. There are two ER subtypes (ER-a and ER-
b), and when ligand bound, the ERs act as hormone-inducible
transcription factors capable of translocation into the nucleus for
themodulation of gene expression.[7,8] Both subtypes are expressed
in the human retina and RPE.[9e11] Human ER-a is also detected in
Fig. 3. A. Spectral domain optical coherence tomography (SD-OCT) of the macula OD demonstrating near-complete resolution of subretinal ﬂuid (SRF) with a small pigment
epithelial detachment (PED) remaining, one month after initial presentation. B. SD-OCT of the macula OD, two months later and after the self-administration of topical hydro-
cortisone cream, revealing large amount of SRF, worse than initial presentation, with underlying PED, and multiple, small hyperreﬂective foci in the outer plexiform and outer
nuclear layers. C. SD-OCT of the macula OD, two months after the cessation of tamoxifen, revealing near-complete resolution of SRF. There is ellipsoid zone band loss and granularity
subfoveally with a small remaining PED.
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epithelium.[10] While studies suggest a predominance of ER-b over
ER-a, especially in the ganglion cell layer and choroid, ER-a
expression varies considerably with gender and age, with highest
amounts present in young, premenopausal women and little to
none present in men and postmenopausal women.[9,10,12] Inter-
estingly, those with the most reduced ER-a levels are the ones with
an increased incidence of CSCR: males (6:1) and postmenopausal
women.[13,14] Perhaps, a reduced expression of ER-a relative to ER-b
in these patients plays a role in the epidemiology of CSCR. In the
case of our patient, the use of tamoxifen may have resulted in a
decrease in the protective effects of estrogen and ER-a in the
choroid and RPE.
Extensive work has demonstrated the protective effects of es-
trogen in ocular tissues. Estrogen deﬁciency is linked to the
development of dry eyes and age-related macular degeneration
(AMD) in women.[15e18] Conversely, hormone replacement therapyin postmenopausal women is linked by some researchers to a
decreased risk of glaucoma, central retinal vein occlusion, idio-
pathicmacular hole, cataract, and AMD [19e24], although the latter is
disputed.[9,25,26] At the cellular and mitochondrial level, estrogen
protects the human RPE from in vitro oxidative stress in an ER-
dependent fashion, with 17-b estradiol (an ER-b ligand) affording
greater protection than 17-a estradiol (a weak ER-a ligand) in a
male-derived cell line.[11] It is not known whether 17-a estradiol
would have a more protective effect in a cell line with greater ER-a
expression, for example in a premenopausal, female-derived RPE
cell line.
Tamoxifen in vitro causes structural changes to the human RPE
cytoskeleton [27], and is toxic to the human RPE and photorecep-
tors.[28,29] This toxicity is driven by caspase-dependent and
caspase-independent cell death pathways; the effect is dose-
dependent, causing rapid cell death at high concentrations, but
even at lower concentrations, it demonstrates cumulative insult to
Fig. 4. A. Fundus autoﬂuorescence OD revealing subtle hyperautoﬂuorescence inferior to the fovea. B. Fundus autoﬂuorescence OS which is normal in appearance.
Fig. 5. A. Swept source optical coherence tomography (SS-OCT) OD with choroidal thickness measuring an average of 443 ± 44.3 mm and 491 mm subfoveally OD. B. SS-OCT OS with
choroidal thickness measuring an average of 405 ± 43.1 mm and 432 mm subfoveally OS. C. SS-OCT OD, two months after cessation of tamoxifen, with choroidal thickness measuring
an average of 414 ± 46.4 mm and 451 mm subfoveally OD. There was a statistically signiﬁcant decrease in choroidal thickness OD two months after cessation of tamoxifen
(p ¼ 0.0098). D. SS-OCT OS, two months after cessation of tamoxifen, with choroidal thickness measuring an average of 415 ± 38.9 mm and 422 mm. There was no signiﬁcant
difference in choroidal thickness OS before and two months after cessation of tamoxifen (p ¼ 0.35).
Fig. 6. A. Microperimetry four months after discontinuation of tamoxifen revealed a central scotoma OD. VA remained 20/200. B. Microperimetry OS was normal with VA of 20/20.
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detachment occurred within three weeks of initiating low-dose
tamoxifen. After the cessation of tamoxifen, within three weeks,
there was improvement of the SRF and PED, and signiﬁcant
reduction of choroidal thickness OD from 443 ± 44.3 mm (491 mm
subfoveally) to 414 ± 46.4 mm (451 mm subfoveally; p < 0.01). These
ﬁndings may represent a restoration of the protective effects of
estrogen on ER-a after the cessation of tamoxifen.Our patient was treated with docetaxel, carboplatin, pertuzu-
mab, leuprolide, pegﬁlgrastim, and dexamethasone during the
course of her chemotherapy, and treatment with these agents had
been completed ﬁve months prior to her presentation, making it
lower in likelihood that they were acutely responsible for her
presentation. Severe ocular toxicity has been reported with these
agents, but such a delayed onset of toxicity has not been reported.
Although the patient had received eight months of trastuzumab
N. Koulisis et al. / American Journal of Ophthalmology Case Reports 3 (2016) 8e13 13therapy at the time of presentation, ocular toxicity from this is
unlikely. Only one case of trastuzumab toxicity has been re-
ported.[30] The patient presented with bilateral visual acuity loss,
hemorrhage and hard exudates on funduscopy, and bilateral cystic
macular edema, and subretinal ﬂuid on SD-OCT, which began three
months after initiating trastuzumab.
Our patient’s clinical presentation posed a diagnostic and ther-
apeutic dilemma. The initiation of tamoxifen may have represented
a hormonal tipping point in a patient who had previously under-
gone chemotherapy and treatment with steroids, and who had a
predisposition for CSCR. Since our patient was previously on ste-
roids during her course of chemotherapy and did not have any vi-
sual symptoms, tamoxifen may have increased the risk of CSCR in
our premenopausal patient. This may represent a “two-hit”
mechanism involving toxicity to the RPE. Whether this involves
two separate molecular pathways or overlapping pathways is not
clear. Based on the sudden and irreversible vision loss in this case, it
is reasonable to counsel patients to closely self-monitor for changes
in their vision with Amsler grid while taking both steroids and
tamoxifen. We recommend prompt evaluation by an ophthalmol-
ogist in those patients on tamoxifen who report ﬂoaters, scotoma,
or decreased vision. Treatment in these patients should be coor-
dinated together with the patient’s oncologist.
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